双-(4-甲氧基苄基)-胺 | 17061-62-0

• 物质功能分类: 有机原料 - 氨基化合物 - 含氧基氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 双-(4-甲氧基苄基)-胺
• 中文别名: 双(4-甲氧基苄基)胺
• 英文名称: N,N-bis(p-methoxybenzyl)amine
• 英文别名: bis(4-methoxybenzyl)amine；1-(4-methoxyphenyl)-N-[(4-methoxyphenyl)methyl]methanamine；bis(p-anisyl)amine；N,N-bis(4-methoxybenzyl)amine；bis[(4-methoxyphenyl)methyl]amine；(PMB)₂NH
• CAS: 17061-62-0
• 化学式: C₁₆H₁₉NO₂
• mdl: MFCD00277836
• 分子量: 257.332
• InChiKey: HBKPDEWGANZHJO-UHFFFAOYSA-N

物化性质

• 熔点：
  35-37℃
• 沸点：
  384℃
• 密度：
  1.073
• 闪点：
  161℃
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险等级：
  8
• 危险品标志：
  Xi
• 海关编码：
  2922299090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P280,P301+P330+P331,P305+P351+P338,P310,P303+P361+P353
• 危险品运输编号：
  3259
• 危险性描述：
  H314
• 储存条件：
  存于室温、干燥且密封的环境中。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Bis-(4-methoxybenzyl)-amine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H314: Causes severe skin burns and eye damage
H318: Causes serious eye damage
P260: Do not breathe dust/fume/gas/mist/vapours/spray
P303+P361+P353: IF ON SKIN (or hair): Remove/Take off immediately all contaminated clothing. Rinse skin with
water/shower
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P301+P330+P331: IF SWALLOWED: Rinse mouth. Do NOT induce vomiting
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ingredient name: Bis-(4-methoxybenzyl)-amine
CAS number: 17061-62-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C16H19NO2
Molecular weight: 257.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN3259 Class: 8 Packing group: III
Proper shipping name: AMINES, SOLID, CORROSIVE, N.O.S. OR POLYAMINES, SOLID, CORROSIVE, N.O.S. (Bis-
(4-methoxybenzyl)-amine)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

双-(4-甲氧基苄基)-胺是一种胺类有机物，常作为医药中间体使用。

其制备方法是将4-甲氧基苯甲醛与4-甲氧基苄基胺通过还原胺化反应合成得到。

反应信息

• 作为反应物：
  描述：

  双-(4-甲氧基苄基)-胺 在 碘苯 、 铁粉 、 potassium carbonate 、 氯化铵 、 间氯过氧苯甲酸 作用下， 以 乙醇 、 二氯甲烷 、 水 、 二甲基亚砜 为溶剂， 反应 28.0h， 生成 2-(4-甲氧基苯基)-1-[(4-甲氧基苯基)甲基]苯并咪唑
  参考文献：
  名称：

  An intramolecular C(sp³)–H imination using PhI–mCPBA

  摘要：

  开发可持续方法来活化较不活泼的无向C(sp³)–H键在有机合成中具有挑战性但是受欢迎。本手稿展示了使用PhI (10 mol%)–mCPBA作为有机催化剂进行脱氢C–H亚胺化反应，实现对酸性C(sp³)–H基团的选择性活化。

  DOI：

  10.1039/c8cc09100e
• 作为产物：
  描述：

  4-甲氧基苄胺 在 甲醇 、 sodium tetrahydroborate 、 sodium sulfate 作用下， 以 二氯甲烷 为溶剂， 生成 双-(4-甲氧基苄基)-胺
  参考文献：
  名称：

  [2]轮烷内葡糖酰胺的反应性：高反应性α-酮酰胺的机械键控制化学选择性合成及其光触发环化

  摘要：

  葡糖酰胺的机械联锁对于它们化学选择性氧化为 β,γ-不饱和 α-酮酰胺至关重要。这些前所未有的物种令人满意地用于蓝光驱动的环化中，通过 Norrish/Yang II 型反应的两种模式以不同方式提供羟基-2-氮杂环丁酮或恶唑烷酮。这种行为与相同反应条件下非互锁底物的行为截然不同。

  DOI：

  10.1002/anie.202302681

文献信息

• [EN] NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] NOUVEAUX COMPOSÉS ET COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT POUR LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
  申请人：GALAPAGOS NV

  公开号：WO2017012647A1

  公开（公告）日：2017-01-26

  The present invention discloses compounds according to Formula (I), wherein R1, R3, R4, R5, L1, and Cy are as defined herein. The present invention also provides compounds, methods for the production of said compounds of the invention, pharmaceutical compositions comprising the same and their use in allergic or inflammatory conditions, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 and/or interferons. The present invention also methods for the prevention and/or treatment of the aforementioned diseases by administering a compound of the invention.

  本发明公开了根据式（I）的化合物，其中R1、R3、R4、R5、L1和Cy如本文所定义。本发明还提供了该发明的化合物、制备该化合物的方法、包括相同化合物的药物组合物以及它们在过敏或炎症症状、自身免疫疾病、增殖性疾病、移植排斥、涉及软骨周转障碍的疾病、先天软骨畸形和/或与IL6和/或干扰素过度分泌相关的疾病中的使用。本发明还提供了通过给予该发明的化合物来预防和/或治疗上述疾病的方法。
• [EN] SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN<br/>[FR] COMPOSÉS DE SULFONYLE QUI INTERAGISSENT AVEC LA PROTÉINE RÉGULATRICE DE LA GLUCOKINASE
  申请人：AMGEN INC

  公开号：WO2013123444A1

  公开（公告）日：2013-08-22

  The present invention relates to sulfonyl compounds that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

  本发明涉及与葡萄糖激酶调节蛋白相互作用的磺酰基化合物。此外，本发明涉及使用这些化合物或其药学上可接受的盐治疗2型糖尿病和其他涉及葡萄糖激酶调节蛋白的疾病和/或症状的方法，以及含有这些化合物或其药学上可接受的盐的药物组合物。
• Chemoselective reductive alkylation of ammonia with carbonyl compounds: synthesis of primary and symmetrical secondary amines
  作者：Bruhaspathy Miriyala、Sukanta Bhattacharyya、John S Williamson

  DOI：10.1016/j.tet.2003.12.024

  日期：2004.2

  efficient, general procedure for highly chemoselective reductive mono-alkylation of ammonia with ketones is reported. Treatment of ketones with ammonia in ethanol and titanium(IV) isopropoxide, followed by in situ sodium borohydride reduction, and a straightforward workup afforded primary amines in good to excellent yields. Reductive alkylation of ammonia with aldehydes, on the other hand, afforded the corresponding

  报道了一种高效的通用方法，用于用酮对氨进行高度化学选择性的还原性单烷基化。用乙醇和异丙醇钛（IV）中的氨处理酮，然后原位还原硼氢化钠，并直接进行后处理，得到的伯胺的收率好至极佳。另一方面，氨与醛的还原烷基化选择性地提供了相应的对称仲胺。
• METALLO-BETA-LACTAMASE INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20160333021A1

  公开（公告）日：2016-11-17

  The present invention relates to compounds of formula (I) that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

  本发明涉及式(I)的化合物，这些化合物是金属β-内酰胺酶抑制剂，以及这些化合物的合成和与β-内酰胺类抗生素一起用于克服耐药性的用途。
• [EN] COMPOUNDS THAT INHIBIT MCL-1 PROTEIN<br/>[FR] COMPOSÉS INHIBANT LA PROTÉINE MCL-1
  申请人：AMGEN INC

  公开号：WO2018183418A1

  公开（公告）日：2018-10-04

  Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (I), or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

  本文提供了髓样细胞白血病1蛋白（Mcl-1）抑制剂，其制备方法，相关的药物组合物，以及使用这些物质的方法。例如，本文提供了化合物的化学式（I）或其立体异构体；以及这些化合物的药用盐和含有这些化合物的药物组合物。本文提供的化合物和组合物可以用于治疗癌症等疾病或症状。